The FDA needs to do more to protect the safety of kidney dialysis patients who are given high doses of the anemia drug Epogen in clinics, says Dr. Ajay Singh, a clinical chief of the renal division at Brigham and Women's Hospital. Singh, a researcher whose trial of a similar drug had to be halted last year because of safety issues, said there is a trend of higher dosing for dialysis patients and the FDA needs to intervene.

Related Summaries